Part, Chapter, Paragraph
1 I, 2. 10. 4(11)| Her effect van elektronisch voorschrijven
2 I, 2. 10. 4(11)| barcodescanning op het optreden van medicatie toedienfouten”,
3 I, 3. 4 | Henkens K (2001): De timing van het eerste kind in Nederland
4 I, 3. 4 | Meningen en opvattingen van de bevolking over aspecten
5 I, 3. 4 | bevolking over aspecten van het bevolkingsvraagstuk
6 II, 4. 1 | latter by means of the GALI (van Oyen et al, 2006). The HLY
7 II, 4. 3 | and Human Services: 34.~ ~Van Oyen, H., J. van der Heyden,
8 II, 4. 3 | 34.~ ~Van Oyen, H., J. van der Heyden, et al. (2006):
9 II, 5. 2. 6 | Aravanis C, Blackburn HW, Van Buchem FS, Buzina R, Djordjević
10 II, 5. 5. 1 | 41.~ ~Värnik A, Kölves K, van der Feltz-Cornelius CM, Mar , (
11 II, 5. 5. 3 | Berkman et al, 2007; Hoek and van Hoeken, 2003).~ ~Reviewed
12 II, 5. 5. 3 | and studies by Hoek and van Hoeken (2003) for several
13 II, 5. 5. 3 | and studies by Hoek and van Hoeken (2003) for several
14 II, 5. 5. 3 | 25 remains low (Hoek and van Hoeken, 2003). An average
15 II, 5. 5. 3 | number is rising (Hoek and van Hoeken, 2003). Time trends
16 II, 5. 5. 3 | constant until 1990 (Hoek and van Hoeken, 2003). Hoek and
17 II, 5. 5. 3 | Hoeken, 2003). Hoek and van Hoeken (2003) reported a
18 II, 5. 5. 3 | 1 per 100.000 (Hoek and van Hoeken, 2003).~The HBSC (
19 II, 5. 5. 3 | Disorder 41:1 92-95.~Hoek H W, van Hoeken D, (2003): Review
20 II, 5. 5. 3 | in people with epilepsy (Van den Broek and Beghi, 2004).
21 II, 5. 5. 3 | 141-146.~Kotsopoulos IAW, van Merode T, Kessels FGH, et
22 II, 5. 5. 3 | 338:1715-1722.~Smeets VMJ, van Lierop BAG, Vanhoutvin JPG,
23 II, 5. 5. 3 | accessed 10 May 2005).~Van den Broek M, Beghi E, for
24 II, 5. 5. 3 | publication available at http f]~Van Ooteghem P, De Hooghe MB,
25 II, 5. 5. 3 | Neuroepidemiology 13:220-225.~Vukusic S, Van Bockstael V, Gosselin S,
26 II, 5. 5. 3 | Sutcliffe et al, 1985; van de Vijver et al, 2001),
27 II, 5. 5. 3 | Graveland GA, Ott A, Grobbee DE, van der Meche FG, Hofman A (
28 II, 5. 5. 3 | Neurology 43(10):1918-1926.~van de Vijver DA, Roos RA, Jansen
29 II, 5. 6. 3 | the elderly (Picavet and van den Bos, 1997). Musculoskeletal
30 II, 5. 6. 3 | most over the age of 70 (van Saase et al, 1989). For
31 II, 5. 6. 3 | can also be considered (van Staa et al, 2001). The lifetime
32 II, 5. 6. 3 | 25 and 64 years of age (van den Velden et al, 1991).
33 II, 5. 6. 6 | Polder JJ, Koopmanschap MA, van der Maas PJ (1998): Demographic
34 II, 5. 6. 6 | 62:644-650~Picavet HS, van den Bos GA (1997): The contribution
35 II, 5. 6. 6 | de Regt EB, Andries F, van Agt HM, Bijl RV, de Boer
36 II, 5. 6. 6 | Ann Rheum Dis 57:649-655~Van den Velden J, De Bakker
37 II, 5. 6. 6 | in de huisartspraktijk~ ~van Saase JL, van Romunde LK,
38 II, 5. 6. 6 | huisartspraktijk~ ~van Saase JL, van Romunde LK, Cats A, Vandenbroucke
39 II, 5. 6. 6 | Ann Rheum Dis 48:271-280~van Staa TP, Dennison EM, Leufkens
40 II, 5. 7. 1 | 2006b; Cirillo et al, 2006; Van Biesen et al, 2007); these
41 II, 5. 7. 3 | ESRD (Stengel et al, 2003; van Dijk et al, 2005) After
42 II, 5. 7. 3 | RRT patients (Jager and van Dijk 2007) resulted in a
43 II, 5. 7. 3 | is about 60 cases pmarp (Van der Heijden et al, 2004).
44 II, 5. 7. 3 | higher in females (Belgium (Van Biesen et al, 2007) , England (
45 II, 5. 7. 3 | differences in patient survival (van Dijk et al, 2007). International
46 II, 5. 7. 3 | and 56%, respectively (Van Dijk et al, 2001).~ ~In
47 II, 5. 7. 3 | ESRD (Stengel et al, 2003; van Dijk et al, 2005) After
48 II, 5. 7. 3 | RRT patients (Jager and van Dijk 2007) resulted in a
49 II, 5. 7. 4 | general population) (Jager and van Dijk, 2007). Another factor
50 II, 5. 7. 7 | de Vries R, Hillege HL, van Gilst WH, et al (2006):
51 II, 5. 7. 7 | 3):394-9.~Gansevoort RT, van der HB, Stegeman CA, de
52 II, 5. 7. 7 | 141(2):95-101.~Jager KJ, van Dijk PC (2007): Has the
53 II, 5. 7. 7 | 6.~Stengel B, Billon S, van Dijk PC, Jager KJ, Dekker
54 II, 5. 7. 7 | PE, O'donoghue DJ, de LS, Van VJ, Klebe B, Middleton R,
55 II, 5. 8. 7 | 1973-1980.~ ~Mohangoo AD, van der Linden MW, Schellevis
56 II, 5. 8. 7 | Olivieri M, Villani S, Van Sprundel M, Antó JM, and
57 II, 5. 8. 7 | Care Med. 172:1139-1145.~ ~Van Schayck CP, Loozen JM, Wagena
58 II, 5. 8. 7 | EJ, Kant I, Huibers MJ, van Amelsvoort LG, Swaen GM,
59 II, 5. 8. 7 | LG, Swaen GM, Wouters EF, van Schayck CP. Psychological
60 II, 5. 10. 7 | Pumphrey RSH, Stahl Skov P, van Ree R, Vlieg-Boerstra BJ,
61 II, 5. 10. 7 | C, Botjes E, Crevel RWR, van Ree R (2007): The prevalence,
62 II, 5. 10. 7 | Stern M, Ciclitira PJ, Van Eckert R, Feighery C, Janssen
63 II, 5. 11. 3 | young healthy populations (van Coevorden et al, 2004).~ ~
64 II, 5. 11. 7 | Springer-Verlag, 1991,9.~ ~Van Coevorden AM, Coenraads
65 II, 5. 15. 1 | genetically determined (van Weely and Leufkens, 2004;
66 II, 5. 15. 6 | drugs. Available at: htt et~Van Weely S, Leufkens HGM (2004):
67 II, 8. 2. 1 | population (Straetmans, van Schrojenstein Lantman-de
68 II, 8. 2. 1 | population and clinical levels (van Schrojenstein Lantman-de
69 II, 8. 2. 1 | For example, Straetmans, van Schrojenstein Lantman-de
70 II, 8. 2. 1 | Straetmans, J.M.J.A.A., H.M.J. van Schrojenstein Lantman-de
71 II, 8. 2. 1 | www.eurohealthnet.eu>~Van Schrojenstein Lantman-de
72 II, 8. 2. 1 | Research, 51, 6, 427-434.~van Schrojenstein Lantman-de
73 II, 8. 2. 1 | press.~Walsh PN, Kerr M.P, van Schrojenstein Lantman-de
74 II, 8. 2. 1 | Linehan, C., Kerr, M., van Schrojenstein Lantman-de
75 II, 8. 2. 1 | Garrido-Cumbrera, M., van Hove, G., Björkman, M.,
76 II, 9. 1. 1 | Kuijpers JC, Meershoek AP, van Velzen D (1998): Contribution
77 II, 9. 1. 1 | Health Statistics, 1992.~ ~Van Reempts P, Gortner L, Milligan
78 II, 9. 1. 1 | Pediatrics 2007;120(4):e815-25.~ ~van Roosmalen J, Schuitemaker
79 II, 9. 1. 1 | Schuitemaker NW, Brand R, van Dongen PW, Bennebroek Gravenhorst
80 II, 9. 1. 2 | supplementation (De Walle and de Jong van den Berg, 2007). Some European
81 II, 9. 1. 2 | 17.~De Walle HE, de Jong van den Berg LT (2007): Growing
82 II, 9. 1. 2 | Reuvers M, Robert E, Rost van Tonningen M, Scialli A,
83 II, 9. 3. 2 | 2006) or the Netherlands (van Roosmalen et al, 2002).~ ~
84 II, 9. 3. 2 | impact on their health (Van Reempts, 2007).~ ~A key
85 II, 9. 3. 2 | Kuijpers JC, Meershoek AP, van Velzen D (1998): Contribution
86 II, 9. 3. 2 | 764-70.~ ~Schuitemaker N, van Roosmalen J, Dekker G, van
87 II, 9. 3. 2 | van Roosmalen J, Dekker G, van Dongen P, van Geijn H, Bennebroek
88 II, 9. 3. 2 | Dekker G, van Dongen P, van Geijn H, Bennebroek Gravenhorst
89 II, 9. 3. 2 | Health Statistics, 1992.~ ~Van Reempts P, Gortner L, Milligan
90 II, 9. 3. 2 | Pediatrics 2007;120(4):e815-25.~ ~van Roosmalen J, Schuitemaker
91 II, 9. 3. 2 | Schuitemaker NW, Brand R, van Dongen PW, Bennebroek Gravenhorst
92 II, 9. 4. 7 | De Henauw S., Schroll M., Van Staveren Wa. (2004): Abstract:
93 III, 10. 1. 3 | Lopez AD, Rodgers A, Hoorn S van der, Murray CJL et al (2002):
94 III, 10. 2. 1 | Arnadottir IB, Ketley CE, Van Loveren C, Seppa L, Cochran
95 III, 10. 2. 1 | Whelton HP, Holbrook WP, van Loveren C, Fernandes B,
96 III, 10. 2. 1 | Miermans PJ, Tafforeau J, van der Heyden J (2006): Gezondheidsenquête
97 III, 10. 2. 1 | G, Bueno-de-Mesquita HB, van der Schouw YT, Engeset D,
98 III, 10. 2. 1 | Pettersson U, Palmqvist R, Van Guelpen B, Bingham SA, McTaggart
99 III, 10. 2. 4 | Sleegens K, Prince JA, van Duijn CM, Kehoe PG (2005):
100 III, 10. 3. 1 | available (Babisch, 2008; Van Kempen et al., 2002).~ ~
101 III, 10. 3. 1 | SC 1 N 1313.~Kempen EEMM van, Kruize H, Boshuizen HC,
102 III, 10. 3. 1 | Staatsen BAM, Overveld AJP van, Ameling CB. Trends in the
103 III, 10. 3. 1 | R (2003). Kwantificering van gezondheidsrisico’s aan
104 III, 10. 3. 1 | gezondheidsrisico’s aan de hand van DALYs en externe gezondheidskosten {
105 III, 10. 3. 1 | Studie uitgevoerd in opdracht van de Vlaamse Milieumaatschappij,
106 III, 10. 3. 1 | night. Edited by: Berg M van den. World Health Organization
107 III, 10. 3. 2 | Ravindra, K, L Bencs, R van Grieken (2004): Platinum
108 III, 10. 4. 2 | recent years~Monitoring~Van Kasteren, 2000;~Richard
109 III, 10. 4. 2 | Richard et al., 2001;~Fiolet & van Veen, 2001~ ~ ~ ~ ~Pesticides
110 III, 10. 4. 2 | monitoring by random~sampling~ ~Van der Schee, 2002;~KAP, 2003~ ~
111 III, 10. 4. 2 | Taylor & Lehrer, 1996;~van Loveren, 2002; (see~textbox
112 III, 10. 4. 2 | Richard et al., 2003;~ Sizoo & van Egmond,~2004; WHO, 1998~ ~
113 III, 10. 4. 2 | Dutch fishing~grounds~ ~ ~Van Apeldoorn et al.,~2004~ ~
114 III, 10. 4. 2 | grounds~temporarily closed~ ~Van Apeldoorn et al.,~2004~ ~
115 III, 10. 4. 2 | for scallops in~Scotland~ ~Van Apeldoorn et al.,~2004~ ~
116 III, 10. 4. 2 | effects~ ~None~ ~Monitoring~Van Apeldoorn et al.,~2004~ ~
117 III, 10. 4. 2 | 1995 in Ireland~Monitoring~Van Apeldoorn et al.,~2004~ ~ ~
118 III, 10. 4. 2 | not be~eaten~ ~Speijers & van Egmond,~1999~ ~Pyrrolizidine
119 III, 10. 4. 2 | exposure~Monitoring~Speijers & van Egmond,~1999~ ~Anisatin~
120 III, 10. 5. 2 | A large Dutch survey (Van Bergen et al., 2006) brought
121 III, 10. 5. 2 | Presentation held by Jouke van der Zee et al. (Netherlands
122 III, 10. 5. 2 | study. BMJ, 317: 576-8.~ ~Van Bergen JEAM et al. (2006):
123 III, 10. 6. 1 | risk for victimization (Van Dijk et al, 2005).~ ~Figure
124 III, 10. 6. 1 | Epidemiology 2006;163:1012–1017~Van Dijk J, Manchin R, Van Kesteren
125 III, 10. 6. 1 | 1017~Van Dijk J, Manchin R, Van Kesteren J, Hideg G, Nevala
126 III, 10. 6. 2 | Geurts JJM, Lahelma E, Van Oyen H, Rasmussen NK, Regidor
127 IV, 11. 1. 4 | care in most countries (van Doorslaer et al, 2004).
128 IV, 11. 1. 4 | for number of visits) (van Doorslaer et al, 2004).
129 IV, 11. 6. 2 | expenditure are tax-deductible (Van Doorslaer et al, 1999).
130 IV, 11. 6. 2 | without this insurance (van Doorslaer et al, 2004; Mossialos
131 IV, 11. 6. 3 | lower income (De Graeve and Van Ourti, 2003). The distribution
132 IV, 11. 6. 3 | regressive (De Graeve and Van Ourti, 2003). In Germany,
133 IV, 11. 6. 3 | Wagstaff, 2002) (De Graeve and Van Ourti, 2003; Musgrove, 2003).
134 IV, 11. 6. 4 | risk selection activities (van de Ven et al, 2003). Even
135 IV, 11. 6. 4 | competition among insurance funds (van de Ven et al 2007).~ ~Table
136 IV, 11. 6. 5 | 881-906.~ ~De Graeve D, Van Ourti T (2003): The distributional
137 IV, 11. 6. 5 | European Communities.~ ~van de Ven W, Beck K et al. (
138 IV, 11. 6. 5 | Health Policy 65: 75-98.~ ~van Doorslaer E, Koolman X et
139 IV, 11. 6. 5 | Economics 13(7): 629-647.~ ~van Doorslaer E, Masseria C
140 IV, 11. 6. 5 | countries. Paris, OECD.~ ~Van Doorslaer E, Wagstaff A
141 IV, 11. 6. 5 | 103-115.~ ~Wagstaff A, van Doorslaer E et al., Eds. (
142 IV, 13. 2. 3 | the Netherlands.~ ~Source: Van Kreil et al (2006)~ ~DALYs
143 IV, 13. 9 | Lopez AD, Rodgers A, Hoorn S van der, Murray CJL et al (2002):
144 IV, 13. 9 | United Nations, New York.~ ~Van Kreil et al (2006) Our food,
